![Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy - Hartrampf - 2022 - The Prostate - Wiley Online Library Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy - Hartrampf - 2022 - The Prostate - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c5def381-c67b-46da-881e-29654ef69718/pros24414-fig-0003-m.jpg)
Any decline in prostate‐specific antigen levels identifies survivors scheduled for prostate‐specific membrane antigen‐directed radioligand therapy - Hartrampf - 2022 - The Prostate - Wiley Online Library
![Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-96170-5/MediaObjects/41598_2021_96170_Fig1_HTML.png)
Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment | Scientific Reports
Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy | PLOS ONE
![Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future | Nature Reviews Urology Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future | Nature Reviews Urology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41585-022-00638-6/MediaObjects/41585_2022_638_Fig1_HTML.png)
Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future | Nature Reviews Urology
![Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology](https://jcp.bmj.com/content/jclinpath/61/9/1038/F1.large.jpg)
Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy? | Journal of Clinical Pathology
![Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy](https://www.frontiersin.org/files/Articles/656444/fonc-11-656444-HTML/image_m/fonc-11-656444-t003.jpg)
Frontiers | Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy
![Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis - ScienceDirect Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0923753419314887-gr2.jpg)
Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis - ScienceDirect
![Frontiers | Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone Frontiers | Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone](https://www.frontiersin.org/files/Articles/946060/fonc-12-946060-HTML/image_m/fonc-12-946060-g001.jpg)
Frontiers | Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml | PLOS ONE
![Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus](https://www.eu-focus.europeanurology.com/cms/attachment/f88739ff-71c0-4bf0-935f-361ae3f12d77/gr1_lrg.jpg)
Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? - European Urology Focus
![Race-Specific Trends in Prostate Cancer Screening and Presentation before and after the 2012 United States Preventive Services Task Force Statement | Urology Practice Race-Specific Trends in Prostate Cancer Screening and Presentation before and after the 2012 United States Preventive Services Task Force Statement | Urology Practice](https://www.auajournals.org/cms/asset/c7560027-7ce5-4009-b22c-828894a62298/upj.0000000000000274f1.gif)